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SUMMARY
Select lectins have powerful anti-viral properties that effectively neutralize HIV-1 by targeting the 
dense glycan shield on the virus. Here, we reveal the mechanism by which one of the most potent 
lectins, BanLec, achieves its inhibition. We identify that BanLec recognizes a subset of high-
mannose glycans via bidentate interactions spanning the two binding sites present on each BanLec 
monomer that were previously considered separate carbohydrate recognition domains. We show 
that both sites are required for high-affinity glycan binding and virus neutralization. Unexpectedly 
we find that BanLec adopts a tetrameric stoichiometry in solution whereby the glycan-binding 
sites are positioned to optimally target glycosylated viral spikes. The tetrameric architecture, 
together with bidentate binding to individual glycans, leads to layers of multivalency that drive 
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viral neutralization through enhanced avidity effects. These structural insights will prove useful in 
engineering successful lectin therapeutics targeting the dense glycan shield of HIV.
Graphical abstract
INTRODUCTION
An estimated 37 million people worldwide are HIV positive, with the majority living in sub-
Saharan Africa where infection rates disproportionately affect women due to gender 
inequality and social norms restricting intervention practices (World Health Organization, 
2011). Eradicating HIV will therefore require parallel interventions to limit viral 
transmission, including physical barrier methods, anti-retrovirals, and continuing vaccine 
development, as well as social and behavioral education (Ananworanich and Fauci, 2015; 
Burton et al., 2012; François and Balzarini, 2012). A key role in this battle will likely be 
played by HIV microbiocides, agents that act to reduce the infectivity of the virus during 
sexual contact (Brichacek et al., 2013). Lectins have recently emerged as attractive 
microbiocide candidates which could be applied topically or even produced in situ by 
engineered commensal microbes (Lagenaur et al., 2015), and work by limiting transmission 
at mucosal surfaces (François and Balzarini, 2012; Lagenaur et al., 2015; Liu et al., 2006). 
Several lectins have potent anti-HIV properties in vitro and are therefore desirable starting 
points for development (Boyd et al., 1997; François and Balzarini, 2012; Mori et al., 2005; 
Swanson et al., 2010; Xiong et al., 2006).
Env, the viral spike of HIV, is a trimer of heterodimers of extensively glycosylated gp120 
and gp41 subunits responsible for host-cell recognition and fusion (Julien et al., 2013). 
Glycosylation of Env acts to form a “glycan shield” that impedes antibody neutralization 
(Dacheux et al., 2004). However, infected individuals can develop broadly neutralizing 
antibodies (bnAbs) against the virus, some of which specifically target the glycan surface 
(Crispin and Doores, 2015; Ward and Wilson, 2015). Discrimination of the bnAbs against 
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self-recognition is achieved by the large proportion of high-mannose glycans within the 
glycan shield (Behrens et al., 2016; Bonomelli et al., 2011; Doores et al., 2010; Pritchard et 
al., 2015a). This arises because, while the number of N-glycosylation sites varies between 
viral strains (Korber et al., 2001), their density is consistently high relative to human 
glycoproteins and results in limited cellular processing (Bonomelli et al., 2011). As a result, 
high-mannose type structures, which are a conserved feature of the virus, may be exploited 
in the design of vaccines, therapeutics, and prophylactics (Burton et al., 2012).
Lectins are carbohydrate-binding proteins and several members of the family have been 
shown to bind the HIV virus via its surface glycoproteins, blocking glycan-mediated 
interactions with the CD4 receptor and/or CCR5/CXCR4 co-receptors on host cells. One of 
the most potent anti-viral lectins, BanLec, has been shown to inhibit HIV fusion to HeLa 
cells with half-maximal inhibitory concentration (IC50) values in the low-nanomolar range 
(Swanson et al., 2010). While N-glycan specificity has been well characterized for many 
anti-viral lectins (Bewley and Otero-Quintero, 2001; Botos et al., 2002; Koharudin and 
Gronenborn, 2011; Moulaei et al., 2010; Shenoy et al., 2002), there is no equivalent 
understanding of the intermolecular interactions between BanLec and HIV glycans. 
However, from X-ray crystallography structures it has been suggested that BanLec is a 
dimeric protein with each monomer containing two carbohydrate-binding sites (Meagher et 
al., 2005; Sharma and Vijayan, 2011; Singh et al., 2004, 2005). Crystallographic and 
molecular dynamics (MD) studies have reported BanLec-binding specificity to disaccharides 
with α-1,3-mannosyl linkages in both binding sites (Sharma and Vijayan, 2011), and 
BanLec-HIV recognition is expected via mannose epitopes on high-mannose N-glycans. A 
binding model was proposed recently whereby each binding site acts independently to 
engage viral carbohydrates (Swanson et al., 2015), but was not tested with high-mannose N-
glycans. Protein-carbohydrate interactions are typically weak, with milli- or micromolar 
affinity (Weis and Drickamer, 1996), but can be strengthened through multivalent 
interactions and glycan clustering (e.g., the Env glycan shield).
In this study we investigate BanLec-glycan recognition through a combination of structural 
and functional studies, and provide an explanation for the extraordinary specificity and anti-
viral activity. We propose the first tetrameric structure of BanLec and show that 
carbohydrate-binding sites present on each monomer are not independent, but function 
jointly to engage a single, specific high-mannose glycan that bridges both sites 
simultaneously. These key mechanistic insights will aid successful development of lectin 
therapeutics with superior HIV neutralization through the modulation of multivalent 
interactions to N-linked glycans.
RESULTS
BanLec Inhibits HIV by Targeting Specific High-Mannose gp 120 Glycans
We first sought to identify the gp120 N-glycans targeted by BanLec. To do this we designed 
a depletion assay where fluorescently labeled N-glycans released from HIV gp120 (JRCSF 
strain) were incubated with increasing concentrations of BanLec. The unbound glycans were 
identified by hydrophilic interaction chromatography combined with high-performance 
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liquid chromatography (HPLC). The glycans that possess the highest affinity for BanLec 
were then identified by their preferential depletion.
We found that the predominant N-glycans present were oligomannose structures 
(MannGlcNAc2, n = 5−9, referred to hereafter as Man5–9), with Man8 and Man9 the most 
abundant, in agreement with previous data (Bonomelli et al., 2011). Upon the addition of 
BanLec, the abundance of Man8 and Man9 structures, and to a lesser extent Man7, 
decreased considerably (Figure 1A). Surprisingly, we found that Man5 and Man6 were not 
depleted despite the presence of terminal mannose epitopes which have previously been 
reported to bind to BanLec (Mo et al., 2001; Sharma and Vijayan, 2011). Therefore, BanLec 
binds HIV primarily via the Man8 and Man9 glycans on Env.
We then tested the affinity of BanLec to Man8/9 glycans in vivo by employing an HIV 
neutralization assay. We used two pseudovirus strains (HIVJRCSF and HIVBaL) produced in 
the absence or presence of kifunensine (kif), a potent inhibitor of α-mannosidase. Treatment 
with kif generates virions decorated predominantly with Man8 and Man9 glycans (Doores 
and Burton, 2010). We found that neutralization potency was considerably increased against 
kif-treated virions, leading to IC50 values an order of magnitude lower for HIVJRCSF (25 
pM) and HIVBaL (35 pM) compared with wild-type HIVJRCSF (0.5 nM) and HIVBaL (1.1 
nM) virions (Figure 1B). This reveals that the potency of BanLec is significantly enhanced 
when the HIV envelope proteins are augmented with longer-chain high-mannose structures, 
specifically Man8 and Man9. The difference in IC50 between HIVJRCSF and HIVBaL in the 
presence of kif is likely attributed to the increased number of glycosylation sites on HIVBaL 
strains. Together, the depletion assay and neutralization data demonstrate that BanLec 
neutralizes HIV via binding primarily to Man9 glycans on Env.
To characterize binding to longer-chain high-mannose glycans, we used native mass 
spectrometry (MS) to measure the stoichiometry and affinity of binding of Man7–9 glycans 
to BanLec. Although BanLec has been previously reported to be a dimeric protein (Meagher 
et al., 2005; Sharma and Vijayan, 2011; Singh et al., 2005; Swanson et al., 2015), we found 
it to exist as a tetramer in the mass spectrum (Figure 2A) (discussed further below). Upon 
incubation with Man9 glycans, we observed BanLec-glycan complexes with between one 
and four Man9 bound (Figure 1C). Importantly, we observed no complexes with higher 
binding stoichiometries (even in the presence of 25 equivalents of glycan), suggesting that 
BanLec-glycan binding stoichiometry is 1:1.
We then calculated dissociation constants (KD) for Man9 binding to BanLec by measuring 
the relative intensity of bound species at different glycan concentrations (Figures S1A–S1C). 
We found that the KDs for all four binding events of Man9 to BanLec are similar, with an 
average value of 7.6 ± 1.0 μM (Figure 1D). Performing the same binding experiments with 
Man8 and Man7 showed that these glycans had the same binding stoichiometry with average 
KDs of 3.8 ± 0.8 μM and 39 ± 7.5 μM for Man8 and Man7, respectively. These binding 
affinities, which are an order of magnitude lower for Man7 than for Man8 and Man9, are 
consistent with the results of the depletion assay. Notably, for all three glycans, each 
successive binding event has a similar KD, implying there is no cooperativity in binding.
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Structural Model of the BanLec Tetramer
Native MS revealed BanLec is a tetrameric protein (with no other stoichiometries observed), 
which was unexpected as previous reports suggested it is a dimeric protein (Meagher et al., 
2005; Sharma and Vijayan, 2011; Singh et al., 2005; Swanson et al., 2015). To validate our 
observation, we examined BanLec by size-exclusion chromatography/multi-angle light 
scattering (SEC-MALS). In agreement with the native MS experiment, BanLec eluted in a 
single peak with a molecular mass of approximately 60 kDa (Figure 2B). We conclude 
therefore that BanLec, in line with other members of the jacalin family of lectins (Pratap et 
al., 2002; Sankaranarayanan et al., 1996), assembles as a tetramer in solution.
To ascertain whether tetramers observed by native MS share an architecture similar to that of 
artocarpin/jacalin (jacalin family lectins) or an asymmetric crystal form, we measured 
BanLec by small-angle X-ray scattering (SAXS). Comparison of the experimental SAXS 
curve and radius of gyration with theoretical scattering and gyration values clearly indicates 
that BanLec is consistently tetrameric, with an architecture similar to that of artocarpin and 
jacalin (Pratap et al., 2002; Sankaranarayanan et al., 1996) (Figure 3).
The assembly of BanLec in previous X-ray crystal structures is a dimer and/or an 
asymmetric tetramer different to that observed for artocarpin and jacalin (Meagher et al., 
2005; Sharma and Vijayan, 2011; Singh et al., 2004; Swanson et al., 2015). Using our 
preparation of BanLec, which we knew to be tetrameric in solution, we solved a crystal 
structure of BanLec in a new crystallization condition. This crystal form was equivalent to 
existing structures (Figure 4A and Table 1) with the arrangement of the dimer similar to that 
in other BanLec structures (root-mean-square deviation [RMSD] values of 0.475 Å [PDB: 
2BMY], 0.464 Å [PDB: 3MIT], 0.464 Å, and 0.505 Å [PDB: 4PIF]), and likewise the 
presence of asymmetric tetramers in the crystal packing (Figure S2) (Meagher et al., 2005; 
Singh et al., 2005; Swanson et al., 2015).
Furthermore, a single tetramer form was distinguished by ion mobility MS (IM-MS) and 
correlated to the SAXS density envelope (Figures 4B and 4C). Two symmetric BanLec 
tetramer models were generated by aligning two copies of the dimeric form with artocarpin 
and by independently docking two BanLec dimers in the SAXS envelope, which had been 
generated from an ab initio structural model from the scattering data (Svergun et al., 2001). 
The symmetric tetramer created from independently docked dimers resulted in a higher 
cross-correlation coefficient than in any other model and represented the best fit to the 
SAXS density envelope. Using IM-MS, the rotationally averaged collision cross-section 
(CCS) was measured, which represents the size and shape of the protein. The CCS of 
BanLec was similar to theoretical CCSs for both symmetric BanLec models and 
significantly different from that of the asymmetric BanLec tetramer. The combined SAXS 
and IM-MS data therefore support a symmetric model of BanLec tetramers, in which the 
architecture is the same as in other members of the jacalin family of lectins (Pratap et al., 
2002; Sankaranarayanan et al., 1996) rather than the asymmetric crystal form.
We then explored whether the tetrameric architecture of BanLec is important for HIV 
inhibition. A variant of BanLec (Y46K) has been reported to reduce tetrameric formation 
observed in the crystal packing (Swanson et al., 2015) and, consistent with this, in our model 
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this residue is located at the tetrameric interface (Figure 4E). By native MS this variant is 
approximately 50% dimer/tetramer, and has noticeably diminished ability to neutralize 
pseudovirus strains compared with wild-type BanLec (Figures 4D and 4F). The IC50 values 
for this variant were 2.9 nM, 4.0 nM, 0.6 nM, and 0.6 nM for HIVJRCSF, HIVBaL, 
HIVJRCSF+kif, and HIVBaL+kif, respectively. These values are 5-, 3-, >24-, and >77-fold 
greater than for wild-type BanLec. Therefore, the tetrameric architecture of BanLec is 
essential for the high potency observed against HIV.
BanLec Binds High-Mannose Glycans via Bidentate Interactions
Notably, in the symmetric model presented here, all carbohydrate-binding sites (two per 
monomer) (Meagher et al., 2005) are on the exterior of the tetramer. The sites on each 
monomer are separated by 40 Å (Figure 4A) and are well positioned for interacting with 
multiple N-glycans simultaneously on different HIV trimers. This arrangement may help to 
explain the propensity of viral particles to become crosslinked and aggregated (Lusvarghi et 
al., 2016). Consistent with this mode of action, when we incubated BanLec and the soluble 
Env trimer mimic BG505 SOSIP.664, we observed aggregation by negative-stain electron 
microscopy (Figure S3) (Sanders et al., 2013, 2015).
The apparent number of glycan-binding sites (two per monomer) is intriguing, because the 
presence of eight independent-binding sites is in disagreement with four being the maximum 
number of high-mannose glycans we were able to observe binding by native MS. This raises 
the possibility that a single glycan can bind simultaneously to the pair of sites on each 
monomer.
To investigate whether a single glycan-binding interaction could involve both sites on each 
monomer, we performed MD simulations (Tessier et al., 2013) to sample sterically allowed 
configurations of glycan binding. Initially, we performed simulations of a small trisaccharide 
(Manα1-2Manα1-3Manα) bound to each binding site present on the BanLec monomer, and 
found that each site had a similar binding strength according to per-residue MM-GBSA 
(Molecular Mechanics/Generalized Born Surface Area) calculations (Table S1). We then 
performed simulations of Man9 binding to BanLec to determine whether two arms of the 
glycan structure could bind simultaneously to both glycan-binding sites on each monomer.
We uncovered seven unique bidentate interaction modes (Figure 5). Six of these modes 
involve the terminal Manα1–2 residue (here termed residue g) on the D1 arm of Man9, 
suggesting that binding is regulated by the ability of larger high-mannose glycans (i.e., 
Man7–9) to bridge both binding sites simultaneously. Using the same per-residue MM-
GBSA MD analysis we calculated the Man9-binding energies for each mode (Table S2). 
Amino acids contributing to hydrogen bonding to mannose (site I: D133 and site II: D38) as 
observed from crystallography studies were also identified in this analysis (Meagher et al., 
2005). However, other residues (G129, K130, and F131) located between each carbohydrate-
binding site also appear to equally contribute to Man9 binding. Interestingly, we consistently 
observed binding-energy contributions from F131. This residue is positioned between the 
glycan-binding sites, suggesting that it may interact with a significant portion of the bound 
Man9.
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To validate a bidentate model of binding, we created mutations (D38G and D133G) in each 
binding site of two residues that hydrogen bond to a mannose monosaccharide (Meagher et 
al., 2005) and that also bind to Man9 in our simulations (Figure 6A). We then recorded mass 
spectra of both variants, in which the proteins were tetrameric, and structurally unperturbed 
as suggested by identical charge-state distributions to the wild-type protein. We then mixed 
each variant with two equivalents of Man9 and compared the mass spectra with those 
obtained for the wild-type protein in the same conditions (Figure 6B). Whereas wild-type 
BanLec bound up to three Man9 glycans per tetramer, for both variants no significant glycan 
binding was detected. Consistent with an important role in glycan binding, the D38G and 
D133G variants possess no neutralization activity toward HIV pseudovirions (Figure 6C). 
D133G has previously been shown to abolish HIV neutralization (Swanson et al., 2015) but 
D38G has not been previously tested. We also characterized the behavior of a variant of 
F131, a residue located in the “saddle” between D38 and D133, which also under these 
conditions did not bind Man9 and for which HIV neutralization was abolished.
Interestingly, when we tested the binding of Man9 with that of another variant, H84T, which 
has been reported to have reduced multivalent interactions (Swanson et al., 2015), the 
binding was similar to that of wild-type BanLec. A maximum of four Man9 glycans could 
be observed bound, with an average KD of 9.5 ± 1.1 μM (Figure S1D). This is in contrast to 
the report by Swanson et al. (2015) of weakened affinity to dimannoside carbohydrates. The 
H84T mutation was proposed to disrupt “the wall that helps create the two independent 
sugar-binding sites” (Swanson et al., 2015), thus reducing multivalent interactions to N-
glycans. Surprisingly, we observed diminished HIV neutralization with H84T variants with 
IC50 of 46.7 nM (HIVJRCSF), 46.8 nM (HIVBaL) 1.7 nM (HIVJRCSF+kifunensine), and 1.1 nM 
(HIVBaL+kifunensine). These results also contradict the reports of Swanson et al. in which 
H84T has neutralization ability equal to that of wild-type BanLec.
In summary, these results demonstrate that BanLec inhibits HIV through binding of Man7–9 
glycans on gp120 and, while each high-mannose glycan interacts with both binding sites in a 
monomer, the two sites are not redundant, but rather are both necessary for competent 
binding and HIV neutralization.
DISCUSSION
How lectins achieve their extremely high potency and breadth of neutralization to HIV, as 
well as other enveloped viruses including Ebola (Barrientos et al., 2003) and influenza 
(O’Keefe et al., 2003), has been an important question in the field. N-linked glycan 
recognition has been reported for other anti-HIV lectins (Botos et al., 2002; Moulaei et al., 
2010; Sato et al., 2011), but no equivalent observation had been made for BanLec. For 
potent neutralization, a lectin must exhibit high affinity and tight binding to the target viral 
spike to account for the nanomolar IC50 values reported. However, the extant biophysical 
understanding of BanLec (Weis and Drickamer, 1996) describes protein-monosaccharide 
interactions six or more magnitudes greater than this, which would be seemingly too weak to 
account for the anti-viral activity. To address this question, we used a variety of biophysical 
approaches to unravel the precise nature of the interactions between BanLec and the HIV 
virus.
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Through a combination of HPLC glycan depletion and HIV neutralization assays, we 
discovered that BanLec binds only to Man7–9 structures, which typically represent >50% of 
the glycan shield (Pritchard et al., 2015b). These results refine the broader specificity 
established in previous lectin assays (Kanagawa et al., 2014; Singh et al., 2005; Swanson et 
al., 2015). By native MS we demonstrated that BanLec is a tetramer in solution, and by 
exploiting the ability of the technique to monitor individual binding stoichiometries (Hilton 
et al., 2013), found that each monomer is capable of binding only a single high-mannose N-
linked glycan. We further quantified Man7–9 KDs to be in the low-micromolar range, 
approximately three orders of magnitude lower than for small mannose sugars (Mo et al., 
2001). By performing MD simulations on Man9 binding we discovered modes by which 
different branches of large multi-antennary glycans can interact with a pair of sites on a 
BanLec monomer, which we could validate with native MS binding assays. This bidentate 
binding would account for the much lower KD of the large antennary glycans compared with 
that for small oligosaccharides, due to avidity effects of a single N-glycan. The avidity 
enhancement ratio (β) of 103 is in line with other bivalent interactions described in the 
literature (Mammen et al., 1998).
However, although it to some extent explains the strong interaction between BanLec and 
HIV, this intra-subunit mechanism does not fully account for viral inhibition at nanomolar 
concentrations. An explanation for this discrepancy comes from our discovery that BanLec 
is a tetramer in solution, rather than a dimer as previously thought. Our (symmetric) 
structural model of BanLec resembles other tetrameric members of the jacalin family of 
lectins and not the asymmetric BanLec tetramer frequently observed in crystal packing of 
the protein. The symmetric model shows that the glycan-binding sites are located at the four 
corners of the tetramer, allowing the lectin to bind Env glycans with minimal steric 
hindrance. As a result, BanLec should be considered as a tetravalent ligand for the HIV 
virion, with each binding site facilitating a strong bidentate interaction with a single high-
mannose glycan.
We also found that both glycan-binding sites on each monomer are not partitioned as has 
been proposed (Swanson et al., 2015), but are equally essential for single glycan recognition. 
Notably the potency of the H84T variant, which was reported to maintain anti-viral 
properties (Swanson et al., 2015), was notably reduced in our hands. Disruption of tetramer 
assembly via the Y46K mutation reduces neutralization potency and highlights the 
importance of a tetrameric stoichiometry for anti-viral activity. These layers of multivalency 
appear to amplify each other, leading to the enhanced binding of single mannose moieties by 
a β factor of 106. The neutralization of HIV is therefore able to be achieved at nanomolar 
concentrations of BanLec.
The ability of BanLec to bind to high-mannose glycans presented across the surface of the 
viral spike underpins both the breadth of viral neutralization and its ability to recognize 
glycans of multiple bnAb epitopes. Furthermore, the large separation between binding sites 
on BanLec likely allows for the recognition of gp120 glycan clusters (Pritchard et al., 
2015a), and raises the possibility that the lectin bridges virion spikes. Evidence for this 
comes from our observation of extensive aggregation when soluble mimics of the viral spike 
are incubated with BanLec. This broad and versatile nature of interaction explains the 
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general potency across HIV strains through specific recognition of conserved high-mannose 
Env glycans, only elements of which are exploited by individual bnAbs. In addition, BanLec 
tetramers may promote interactions between Env proteins, which then could obstruct initial 
receptor recognition or the conformational rearrangements required for fusion of the HIV 
virion with the host membrane.
Recent efforts have established lectins as anti-HIV microbicides of great potential utility. 
However, the limited information on the precise nature of the interactions between BanLec 
and gp120 N-glycans has hampered protein-engineering strategies. The detailed 
understanding we have developed here, regarding both the native glycan targets and their 
binding mechanisms, will greatly inform future developments of successful lectin-based 
anti-viral therapies.
STAR★METHODS
Detailed methods are provided in the online version of this paper and include the following:
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
goat anti-human Fab secondary antibody Thermo Scientific Pierce Cat # PA5-33290
Bacterial and Virus Strains
E. coli BL21 Gold(DE3) cells Agilent Cat# 230132
HEK 293T cells ATCC ATCC 11268
TZM-bl cells NIH ARRRP NIH ARRRP 8129
Chemicals, Peptides, and Recombinant Proteins
BanLec This paper N/A
gp120 (JR-CSF & Bal) This paper N/A
TEV protease This paper N/A
Ampicillin Sigma-Aldrich Cat# A0166
Kanamycin Sigma-Aldrich Cat# K1377
anthranliamide Sigma-Aldrich Cat# A89804
ammonium acetate Sigma-Aldrich Cat# A2706
IPTG Sigma-Aldrich Cat# I5502
kifunensine Sigma-Aldrich Cat# K1140
Protease inhibitor cocktail Roche Cat# 05056489001
luciferase substrate Promega Cat# E1500
PNGase F New England BioLabs Cat# P0705S
Critical Commercial Assays
Phusion High-Fidelity PCR kit New England BioLabs Cat# E0553
Qiagen Gel Extraction kit Qiagen Cat# 28704
In-Fusion HD Cloning Kit Clontech Cat# 639648
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REAGENT or RESOURCE SOURCE IDENTIFIER
Deposited Data
BanLec dimer This paper PDB: 5EXG
Oligonucleotides
Primers for BanLec D38G
Forward:
GTGACATCAACACCGCCAACCACATCGCCAC
Reverse: 
GTGGCGATGTGGTTGGCGGTGTTGATGTCAC
This paper N/A
Primers for BanLec D133G
Forward:
GATAGACACCAATGGCACCCAGGAATTTACCACCA
Reverse:
TGGTGGTAAATTCCTGGGTGCCATTGGTGTCTATC
This paper N/A
Primers for BanLec H84T
Forward:
TGCTAACTACACCGGTGCGGTCGTGC
Reverse:
ACTTCACCTGCCATGCCC
This paper N/A
Primers for BanLec Y46K
Forward:
Forward:
CACCTTCACGAAATACGGCAAAAC
Reverse:
ACATCAACACCGTCAACC
This paper N/A
REAGENT or RESOURCE SOURCE IDENTIFIER
Recombinant DNA
BanLec template DNA Clonetech (based on 
Peumans et al., 2000)
N/A
Plasmid: pET28b Merck-Millipore Cat# 69864
Software and Algorithms
UniDec Marty et al., 2015 unidec.chem.ox.ac.uk.
Empower 3.0 Waters N/A
Masslynx v4.1 Waters N/A
Astra 6.1 software Wyatt Technologies N/A
ATSAS Svergun et al., 2001 https://www.embl-hamburg.de/biosaxs/software.html
Situs Wriggers and Chacon, 
2001
http://situs.biomachina.org/fguide.html
Coot Emsley et al., 2010 http://www.ccp4.ac.uk/
Phaser McCoy et al., 2007 http://www.phaser.com/
Impact Marklund et al., 2015 http://impact.chem.ox.ac.uk/
GLYCAM-Web Kirschner et al., 2008 www.glycam.org
Amber14SB Case et al., 2014 http://ambermd.org/
Other
HisTrap HP column GE Healthcare Cat# 17-5248-02
Superose 6 Increase 10/300 column GE Healthcare Cat# 29-0915-96
Vivaspin 5000 MWCO filter GE Healthcare Cat# 28932223
SDS-PAGE gel Novex NuPAGE Cat# NW04120
Microtitre ELISA plates Corning Cat# 3369
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REAGENT or RESOURCE SOURCE IDENTIFIER
LudgerSep N2 amide HPLC column Ludger Ltd. Cat# LS-N2-4.6x150
Bio SEC-3 SEC column Agilent Cat# 5190-2504
Bio-spin 6 centrifuge columns Bio-Rad Cat# 7326221
METHOD DETAILS
Protein Expression and Purification—BanLec template DNA based on the reported 
sequence from Peumans et al. (Peumans et al., 2000) was purchased from Genscript 
(Piscataway, NJ). BanLec encoding DNA was amplified using a Phusion High-Fidelity PCR 
kit (New England Biolabs) and restriction sites for BamHI and XhoI were introduced and 
the PCR product was purified using a Qiagen Gel Extraction kit and cloned into a linearized 
pET28 vector (cut with BamHI and XhoI) containing a TEV protease-cleavable N-terminal 
polyhistidine tag using In-Fusion HD Cloning Kit (Clontech). Construction of green 
flourescent protein (GFP)-tagged BanLec was performed similarly but with NdeI and NheI 
specific inserts introduced to the PCR product. The PCR product was cloned into a 
linearized pET15 vector containing a TEV-GFP-His tag on the C-terminus. BanLec was 
transformed and expressed in E. coli BL21 Gold(DE3) competent cells (Agilent) and cells 
grown in LB media containing 50 μg/mL ampicillin (pET15) or 25 μg/mL kanamycin 
(pET28) until an OD of 0.6 was reached. Expression of BanLec was induced by the addition 
of isopropyl-D-thio-galactopyranoside (IPTG) to 1 mM, and cells cultured for a further 4 
hours at 37 °C. Cells were pelleted by centrifugation at 5,000 g for 10 min and lysed by use 
of a microfluidiser. Soluble protein was separated from cell debris by centrifugation at 
20,000 g for 20 min. The His-tag protein was purified from the lysate by affinity purification 
with a HisTrap HP column (GE Healthcare). The His-tag was then cleaved by incubation 
with tobacco etch virus (TEV) overnight at room temperature. The cleaved protein was 
purified by reverse Ni-affinity and the purity of the flow-through containing BanLec was 
assessed by SDS-PAGE (Novex NuPAGE) prior to MS.
HIV Inhibition Assays—Pseudovirus was generated in HEK293T cells as described 
(Montefiori, 2005; Singh et al., 2005). Briefly, 293T cells were transfected with plasmids 
expressing the virus backbone PSG-3Δenv and the functional envelope clone at a ratio of 2:1 
using PEI (1 mg/mL, 1:3 PEI:total DNA, Polysciences) according to the manufacturer’s 
instructions. Virus supernatants were harvested after 72 h. Glycosidase inhibitor, 
kifunensine, was added at the time of transfection at a final concentration of 25 μM (Doores 
and Burton, 2010). Neutralization activity of BanLec or HIV bnAb wild-type and mutants 
against pseudovirus in TZM-bl cells was determined as described previously (Montefiori, 
2005; Singh et al., 2005). Briefly, TZM-bl cells were seeded in a 96-well flat bottom plate 
and infected with pseudovirus in the presence of BanLec or HIV bnAb (200 μL total 
volume). Viruses were preincubated with BanLec or HIV bnAb for 1 hat37°C. Luciferase 
reporter gene expression was quantified 72 h after infection upon lysis and addition of 
luciferase substrate (Promega).
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bnAb Competition ELISA—Microtitre ELISA plates (Corning) were coated with 
recombinant gp120JR-CSF (5 μg/mL in PBS) overnight at 4 °C. Plates were washed five 
times with a solution of PBS containing 0.05% Tween 20 (v/v) and then blocked for 1 h at 
room temperature with 5% non-fat milk in PBS + 0.05% Tween (blocking buffer). Plates 
were emptied before addition of a titration of BanLec (starting concentration, 500 μg/mL in 
blocking buffer using a 1:3 dilution series) and incubated for 30–60 min. HIV bnAbs were 
then added at a constant concentration (Ab concentration represented IC50 and were diluted 
in blocking buffer) and incubated for a further 1.5 h. Plates were then washed (×5) and 
alkaline phosphatase (AP)-conjugated goat anti-human Fab secondary antibody (Thermo 
Scientific Pierce) was added at a 1:1000 dilution in blocking buffer and incubated for 1 h. 
Plates were washed (×5) and then AP substrate (50 μL / well) was added. The OD at 405 nm 
was measured after 20 min.
Glycan HPLC—N-glycans were released from 150 μg recombinant gp120 (JRCSF) by 
incubation with PNGase F(New England BioLabs) according to manufacturer’s protocol. 
Glycans were separated from the protein by spin-filtration through 5000 Da MWCO filter 
(Vivaspin, GE Healthcare) and speedvac dried. Released glycans were 2-AB labelled as 
described previously (Struwe and Rudd, 2012). Briefly, glycans were incubated with 20 μL 
1 % formic acid for 45 min at room temperature, and dried before addition of 5 μL 2-AB 
labelling solution (DMSO:glacial acetic acid (7:3 v/v), 1M sodium cyanoborohydride, 0.5 M 
anthranilamide (2-AB)), followed by incubation for 3 h at 65 °C. Excess dye was removed 
by purification with PhyNexus normal phase columns, equilibrated with 95% acetonitrile 
and eluted with 20% acetonitrile. 2-AB labelled glycans were incubated with BanLec for 1 h 
at 37°C for the depletion assays. Unbound 2-AB labelled glycans were separated from 
BanLec-glycan complexes using Vivaspin 500, 5000 Da MWCO spin columns (GE 
Healthcare). Glycans were dried and resuspended in 30 μL 65% CAN prior to analysis using 
a LudgerSep N2 amide HPLC column (Ludger Ltd). Each HPLC injection consisted of N-
glycans released from 10 μg gp120. Analysis was performed using a Waters Acquity system 
with Empower software.
Native Mass Spectrometry—Initial stoichiometry measurements and carbohydrate 
titration experiments were performed on a hybrid quadrupole time-of-flight (q-TOF) mass 
spectrometer modified for high mass transmission (Sobott et al., 2002). Conformational 
analysis was performed using first generation Waters Synapt IM-MS instrument, employing 
a linear drift field to allow direct calculation of collisional cross-sections. Prior to all MS 
analyses, aliquots (50 μL) of BanLec were desalted using Bio-spin 6 (Bio-Rad) centrifuge 
columns, equilibrated with 200 mM ammonium acetate. Following buffer exchange protein 
concentration was measured by absorbance at 280 nm using a UV/Vis spectrophotometer. 
Protein concentrations were then adjusted to between 5 and 10 μM for all MS experiments. 
Typically, 3 μL of protein was loaded into gold-coated nanospray capillaries prepared in-
house and mounted into a static nanospray source block (Hernandez and Robinson, 2007). 
Electrospray was induced by applying a voltage of between 1.1−1.3 kV to the capillary. 
Backing pressure in the source was raised to a pressure of 6−7×10−3 mbar by ‘choking’ the 
line to the roughing pump, improving the transmission of high molecular weight ions. For 
unbound BanLec stoichiometry measurements, sample cone voltages of 60−80 V were used, 
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which provided efficient desolvation and narrower peak widths but with no evidence of any 
induced dissociation. During titration experiments, peak width was compromised to ensure 
no gas-phase dissociation of oligomannose ligands and sample cone was maintained below 
40 V (typically 20 V). To this end, collision energies within the instrument’s collision cells 
were maintained at the minimum values necessary for adequate transmission. This was 
deemed as 10 V in the collision cell of the q-TOF and 5 V in the trap collision cell on the 
Synapt. Transfer cell voltages, which act to provide the linear drift field across the IMS cell, 
were varied over several values to allow calculation of the post-IMS flight time.
For titration experiments, protein and oligomannose aliquots were prepared at twice the 
required concentration and then mixed at a 1:1 ratio to give the desired concentration point. 
Oligomannose stocks were prepared to 150 μM and diluted to the required concentrations in 
milliQ water. Protein concentrations were determined by measuring absorbance at 280 nm. 
Titration experiments were performed at a final ammonium acetate concentration of 100 
mM. Effort was made to ensure that capillary dimensions were kept constant, from the same 
batch and that spray was initiated from a similar capillary-cone distance. Collision energy 
ramps were performed to demonstrate that instrument conditions used during titrations did 
not lead to any gas-phase dissociation. Mass spectra were deconvolved using UniDec into 
zero-charge mass distributions (Marty et al., 2015). Using the UniDec Data Collector 
module, peak [heights] were extracted from the mass distributions and fit to a binding model 
using a least square fitting approach. The software and links to source code are available at 
unidec.chem.ox.ac.uk.
SEC-MALS—Analysis of purified BanLec was performed using an Agilent 1260 HPLC 
with an Agilent Bio SEC-3 SEC column (4.6×150 mm, 3 μm particle, 150 Å pore size) 
coupled to a DAWN HELEOS II scattering detector (Wyatt Technologies) and Optilab T-
rEX (Wyatt Technologies) differential refractive index detector. The MALS detector was 
equilibrated overnight to ensure minimal background light scattering. Roughly 50 μg of 
protein was loaded on-column (column compartment was set to 20 °C) at a flow rate of 0.8 
mL/min in 150 mM sodium phosphate pH 7.5. Data acquisition and analysis were performed 
with Astra 6.1 software (Wyatt Technologies).
X-ray Crystallography—BanLec crystals were grown by hanging-drop vapour diffusion. 
A protein solution [10 mg/mL, in 100 mM NaCl, 20 mM Tris (pH 7.4)] was mixed 1:1 (v/v) 
with a reservoir solution containing 0.05 M NaBr, 0.1 M Bis Tris and 19% PEG-3350 (pH 
7.5). The drop sizes were 1 μL, and the volume of the reservoir solution was 1 mL. The 
crystallisation trays were left at 20 °C. Crystals were harvested and transferred briefly into a 
cryoprotectant composed of 10% glycerol in the reservoir solution. The plate-like crystals 
typically began to form after 24 hours and were fully formed in 72 hours. Data for BanLec 
were collected at Diamond Synchrotron using the I04-1 beamline and were processed using 
XDS and XSCALE. The results are summarised in Table EV1, along with key structure 
refinement details. The protein crystallised in the orthorhombic space group P21212 and 
diffracted to 1.70 Å, with the following unit cell dimensions: a = 63 Å, b = 96 Å, c = 48 Å. 
Cell content analysis indicated high probability of two monomers of BanLec in the 
asymmetric unit. A monomer of BanLec, from PDB 2BMY (stripped of all non-protein 
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atoms) was used as a search molecule for molecular replacement using Phaser. Refinement 
was conducted with Refmac, and electron density maps were analysed with Coot. The 
validation tools of Coot and Molprobity were used to check for and correct conformational 
issues.
SAXS—Data was collected at the B21 bending magnet instrument at Diamond Light 
Source (Harwell, UK). Samples were prepared in200mM ammonium acetate to a 
concentration of 8 mg/mL in a 96 well plate at 5 °C. Protein and corresponding buffer 
solutions were exposed to the beam using an Arinax (Grenoble, France) BioSAXS 
automated sample changer robot, consisting of temperature controlled storage and exposure 
units. The exposure unit contained a 1.6 mm diameter quartz capillary in which the samples 
were illuminated with the X-ray beam; the exposure unit temperature was set to 15 °C. The 
sample capillary was held in vacuum and subjected to a cleaning cycle between each 
measurement. A Pilatus 2M two-dimensional detector was used to collect 180 frame 
exposures of 1 s from each sample and the corresponding buffer. The detector was placed at 
3.9 m from the sample, giving a useful q-range of 0.012 Å−1 < 0.4 Å−1, where q = 4 π 
sin(θ)/λ, where 2θ is the scattering angle and λ is the wavelength, which was set to 1 Å. 
Two dimensional data reduction consisted of normalisation for beam current and sample 
transmission, radial sector integration, background buffer subtraction and averaging. Each 
frame was inspected for the presence of radiation induced protein damage; if this was found 
to be the case, the frames were not reduced and processed. We produced a bead model from 
our BanLec SAXS data using gasbor (Svergun et al., 2001). The resulting model was 
subsequently transformed into a density map using Situs’ pdb2vol tool, and all our BanLec 
structural models docked in it using Situs’ colores tool (Wriggers and Chacón, 2001).
An asymmetrical BanLec tetramer was observed from the crystal packing of our BanLec 
protein preparation. We first produced a BanLec symmetrical tetramer via a structural 
alignment of two of our BanLec dimers onto artocarpin tetrameric structure (pdb: 1J4S). The 
resulting model was subsequently relaxed with 2000 conjugate gradient steps in implicit 
solvent using the NAMD (Phillips et al., 2005) molecular dynamics engine and the 
Amber14SB (Case et al., 2014) force field. We produced a second symmetrical BanLec 
tetramer by directly docking two BanLec dimers into our SAXS density using Situs’ collage 
tool (Birmanns et al., 2011). For all the atomistic models detailed above, the SAXS signal 
was simulated using crysol (Svergun et al., 1995), the radius of gyration predicted with 
Hydropro (Ortega et al., 2011), and the collisional cross-section calculated using Impact 
(Marklund et al., 2015).
Molecular Grafting
Trimannose Structure: A model for bound trimannose oligosaccharide 
(Manα1-2Manα1-3Manα) was built by grafting (Grant et al., 2014; Tessier et al., 2013) the 
required residues onto the co-crystal structure of Manα bound to BanLec (PDBID: 2BMZ).
Bidentate Structure: The 3D structure of Man9 was generated by grafting the required 
branches onto the bound Manα in PDBID: 2BMZ. For grafting, initial conformations for 
Man9 were generated using GLYCAM-Web (www.glycam.org). Structure modelling was 
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used to determine whether Man9 was capable of adopting a low energy conformation that 
would allow two branches of the Man9 oligosaccharide to bind simultaneously in both 
binding sites of BanLec (bidentate binding). A bound Manα residue in one arm was retained 
in the crystallographic orientation, while the intervening glycosidic torsion angles were 
varied within low energy bounds (± 20°) (Nivedha et al., 2013). Any binding modes that 
placed a Manα from a second arm within 2 Å of the second binding site were retained for 
further refinement by energy minimization and molecular dynamics (MD) simulation. This 
procedure was applied to each of the eight Manα residues in Man9.
Energy Minimization and MD Simulation
Bidentate Co-complexes: The MD simulations were performed using the Amber14 
software suite (Case et al., 2014). The Glycam06h (Kirschner et al., 2008) and Amber14SB 
(Case et al., 2014) force fields were employed for carbohydrate and protein respectively. 
Hydrogen atoms were added and protonation states were assigned via tleap using the default 
parameters for Glycam06h and Amber14SB. Energy minimization was performed for 
20,000 steps (10,000 steepest decent, 10,000 conjugant gradient). Following minimization, 
the system was heated over 100 ps from 5 K to 300 K and then equilibrated at 300 K for 
300ps. During the final 200 ps, distance restraints were introduced to guide the desired 
Manα residue into the second binding site (Table S3). The restraints were then turned off 
over a 1 ns period, and the simulation performed without any restraints for a further 10 ns. 
Solvation was treated with the generalized Born approximation (igb = 2) (Onufriev et al., 
2004) throughout with a non-bonded cut-off of 999 Å. The cuda (Gotz et al., 2012; 
Salomon-Ferrer et al., 2013) module was employed for the MD simulations. Pressure and 
temperature were regulated with a Berendsen-type barostat (1 ps constant) and Langevin 
thermostat (2 ps−1 collision frequency) respectively. Scaling factors for 1–4 electrostatic and 
van der Waals interactions were set to unity for glycans (Woods and Chappelle, 2000), and 
1.2 and 2.0 for proteins (Hornak et al., 2006). Covalent bonds to hydrogen were constrained 
with the SHAKE algorithm allowing a 2 fs time step (Ryckaert et al., 1977).
Trimannose Co-complexes: A similar protocol was followed for simulating the trimannose 
co-complexes with the following variations. After the initial minimization, the structure was 
enclosed in a box of explicit TIP3P (Jorgensen et al., 1983) water, with an 8 Å buffer. This 
system was subjected to a second minimization round with 5 kcal/mol/Å2 restraints on non-
hydrogen solute atoms. A 500 ns MD simulation was performed without distance or 
Cartesian restraints. A non-bonded interaction cut-off of 8 Å was applied, beyond which 
long-range electrostatics were treated with the particle-mesh Ewald (PME) method (Darden 
et al., 1993).
Per-residue MM-GBSA: An MM-GBSA calculation (molecular mechanics with 
generalised Born and surface area solvation) with igb = 2 (Onufriev et al., 2004) was 
performed on 1,000 snapshots taken at regular intervals from both the trimannose and Man9 
simulations. The energies were decomposed on a per-residue basis (idecomp = 1).
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CryoEM
Analysis of Lectin-SOSIP Complexes Negative Stain Electron Microscopy (EM): Env 
proteins were prepared for negative stain EM analysis as previously described (Pugach et al., 
2015; Sanders et al., 2013). Briefly, a 3 μL aliquot containing 0.01–0.05 mg/mL of Env 
protein (as determined by UV A280 using the theoretical extinction coefficient based on 
peptide sequence alone) or Env protein in complex with lectin was applied for 5 s onto a 
carbon-coated 400 Cu mesh grid that had been glow discharged at 20 mA for 30 s, then 
negatively stained with nano-W (Nanoprobes, USA) for about 5 s, blotted with filter paper, 
and stained for another 15 s with nano-W. Nano-W was chosen over the more common 
uranyl salts due to the more neutral pH of the stain, which should prevent dissociation 
between pH-sensitive complexes (such as Env-ligand interactions that are strongly governed 
by glycans). Grids were screened to assess stain quality Data were collected on either an FEI 
Tecnai T12 electron microscope operating at 120 keV, with an electron dose of ∼25 e-/Å2 
and a magnification of 52,000 × that resulted in a pixel size of 2.05 Å at the specimen plane, 
or an FEI Talos electron microscope operating at 200 keV, with an electron dose of ∼25 
e-/Å2 and a magnification of 73,000 × that resulted in a pixel size of 1.98 Å at the specimen 
plane. Images were acquired with a Tietz TemCam-F416 CMOS camera (FEI Tecnai T12) 
or FEI Ceta 16M camera (FEI Talos) using a nominal defocus range of 1000–1500. In the 
cases when trimers were visible in the raw images, data were processed using methods 
adapted from those used previously (Pugach et al., 2015). Resulting 2D class averages were 
visually inspected for any Env-lectin complexes.
Analysis of Lectin-SOSIP Complexes by Blue Native Gel Electrophoresis (BN-PAGE) 
and Size-Exclusion Chromatography (SEC): Lectin and BG505 SOSIP.664 were 
combined at varying molar ratios (using the molecular weights of BG505 SOSIP.664 trimer 
and lectin tetramer) of 0.75:1, 1.5:1, 3.75:1, and 7.5:1, incubated at room temperature for 15 
min, and then run on a 4–16% BN-PAGE gel according to manufacturer’s recommendations. 
A separate Lectin and BG505 SOSIP.664 incubated sample (6:1 molar ratio) was subjected 
to centrifugation (14,000 g, 10 min, 4 °C) and loaded onto a Superose 6 Increase 10/300 
column (GE Healthcare). The higher molecular weight peak, corresponding to the expected 
MW for SOSIP.664 trimer, was pooled, concentrated, and analyzed by EM.
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact WBS (weston.struwe@bioch.ox.ac.uk).
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Refer to Web version on PubMed Central for supplementary material.
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In Brief
We present a tetrameric model of the potent anti-HIV lectin BanLec and identify its 
molecular mode of binding to specific high-mannose N-linked glycans. Recognition is 
achieved through bidentate interactions involving different arms of a single N-glycan. 
Together the tetrameric architecture and bidentate binding are critical for HIV 
neutralization.
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Highlights
• Tetrameric structural model of BanLec
• BanLec binds distinct HIV high-mannose N-glycans
• Carbohydrate-binding domains function jointly to bind a single N-glycan
• Altering stoichiometry and bidentate glycan binding affects HIV 
neutralization
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Figure 1. N-Glycan-Binding Assays to BanLec and Inhibition Assays
(A) HPLC depletion assay of released gp120 N-glycans incubated with 0, 1, 5, 10, 20, and 
50 μM BanLec.
(B) Inhibition of HIV pseudovirus strains JRCSF and BaL expressed with and without 
kifunensine (kif).
(C) Native mass spectra of BanLec with different concentrations of Man9 (0, 2.5, 7.5, 15, 
30, and 50 μM).
(D) Kds determined from MS experiments binding Man7, Man8, and Man9 to BanLec, and 
calculated from peak intensities.
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Figure 2. Mass Measurements of BanLec
(A) Native mass spectrum of BanLec gives a mass of 59,394 Da.
(B) SEC-MALS of BanLec with the MALS trace (black circles) indicating a molecular mass 
of ∼60 kDa.
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Figure 3. Small-Angle X-ray Scattering of BanLec
Experimental BanLec (gray) and theoretical SAXS curves of jacalin tetramer (green), 
artocarpin tetramer (red), and BanLec dimer (yellow). Radius of gyration values (Rg) of 
experimental BanLec and theoretical values calculated from BanLec (dimer), jacalin, and 
artocarpin crystal structures are shown.
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Figure 4. BanLec Tetramer Model Generated from SAXS and Native MS
(A) Crystal structure of BanLec with mannose molecules (green, sticks) superimposed from 
PDB: 1X1V. Each of the two carbohydrate-binding domains present per monomer are 
labeled (site I, purple; site II, blue).
(B) Experimental CCS (gray), and theoretical CCS of artocarpin (red), symmetric BanLec 
model (yellow), and asymmetric tetramer (blue). Error bars are from three repeats averaging 
over three charge states.
(C) SAXS density envelope with asymmetric BanLec tetramer (blue), symmetric model 
obtained aligning two BanLec dimers onto artocarpin tetramer (red), and two independent 
BanLec dimers (symmetric tetramer, yellow) fitted into the density. CCC, cross-correlation 
coefficient.
(D) Intact mass spectrum of Y46K BanLec. Two balls indicate dimer charge series, four 
balls is the tetramer charge series.
(E) Symmetric tetramer model with tyrosine (Y46) residues located at the tetrameric 
interface.
(F) Neutralization assay of BanLec Y46K against HIV pseudovirus strains JRSCF and BaL 
expressed with and without kifunensine (+kif).
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Figure 5. Seven Predicted Bidentate Binding Modes of Man9 to BanLec
A cartoon representation of Man9 is shown in with D1, D2, and D3 arms of the structure 
indicated. The individual residues of Man9 are labelled with the letters a to k, and colored 
residues are used to clarify monosaccharide binding to BanLec. The particular Man9 
residues bound in each binding site of the BanLec monomer are indicated in each image. An 
arrow points from the residue bound in site II (D38) to the residue bound in site I (D133).
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Figure 6. HIV Neutralization and Glycan Binding to BanLec Variants
(A) MD-derived positions of Man9 binding to a single BanLec subunit show different glycan 
branches interacting simultaneously to form bidentate binding. BanLec is shown in surface 
representation (yellow) with residues contributing to glycan binding colored: D38, red; 
F131, cyan; D133, pink; H84, orange.
(B) Native mass spectra of wild-type (WT), D38G, D133G, F131G, and H84T variants with 
two molar equivalents Man9 substrate. Peaks corresponding to BanLec-Man9 complexes are 
independently colored.
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(C) HIV neutralization assay of BanLec variants against JRCSF and BaL strains expressed 
with and without kif.
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Table 1
Crystal Parameters, Data Collection, and Refinement Statistics of BanLec
Data Collection
Space group P21212
Cell dimensions
 a, b, c (Å) 63.33, 95.98, 47.53
 a = β = γ (°) 90
Resolution (Å) 19.32−1.70 (1.74−1.70)a
Rmeas 0.137 (1.283)
Mean I/σI 15.77 (2.07)
Completeness (%) 98.8 (96.5)
Redundancy 12.5 (12.6)
Refinement
Resolution (Å) 19.32−1.70 (1.74−1.70)
No. of reflections 30,641
Rwork/Rfree 0.1760/0.2062
No. of atoms
 Protein 2,091
 Ligand/ion 42
 Water 120
Average B factors
 Protein 19.5
 Ligand/ion 21.7
 Water 26.5
RMSDs
 Bond lengths (Å) 0.019
 Bond angles (°) 1.919
aNumbers in parentheses refer to the relevant outer-resolution shell.
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